JAZZ News and Press, Jazz Pharmaceuticals plc From 11/09/22

Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q3 Non-GAAP EPS of $5.17 beats by $0.50 . Revenue of $940.65M (+12.2% Y/Y) in-line. FY2022 Outlook : Raising the mid-point of 2022 total revenue guidance to $3.65B driven by increases in the guidance mid...

Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point PR Newswire DUBLIN , Nov. 9, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quart...

Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research PR Newswire Key data includes results for intravenous administration of Rylaze ® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymph...

Summary Cannabis stocks posted an all-time low in September. Sentiment is terrible. I think the future for the American cannabis industry is bright. Investors should, in my view, invest again or invest initially in cannabis stocks. The cannabis sector recently se...

Summary The lazy way to interpret the tech titans earnings reports last week is to say that Cloud Tech is over. It's not. We organize post market trading we call "fishing" we use it to try and acquire shares at the lowest prices. Alphabet, Amazon, and Microsoft will regain the...

Summary The macroeconomic factors create a highly favorable mergers and acquisition environment. Several interesting deals are being executed this month. As it's a strong buyers' market, you're likely to see more buyouts going toward year-end and next year. Axsome is an ideal ...

Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022 PR Newswire DUBLIN , Oct. 26, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 third quarter financial re...

Summary Jazz Pharmaceuticals will pay $50 million upfront for an option to in-license Zymeworks' zanidatamab. Zymeworks carries most of the risk until Jazz opts in. If the deal goes through, Zymeworks would be in a great position to execute its development plan. The deal offer...

Summary After a barely discernible bottoming process, the rally has become obvious. I got a lot of blowback for taking this position but here we are. The market has fallen so much that it has run out of sellers. There are fundamental reasons why the market can rally here. Will...

Shares of Zymeworks (NYSE: ZYME) were soaring 17% higher as of 10:54 a.m. ET on Wednesday. The big jump came after Zymeworks and Jazz Pharmaceuticals (NASDAQ: JAZZ) announced an exclusive licensing deal for zanidatamab. Jazz will pick up development and marketing rights for ...